X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs FULFORD INDIA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA FULFORD INDIA TORRENT PHARMA/
FULFORD INDIA
 
P/E (TTM) x 25.9 398.8 6.5% View Chart
P/BV x 6.3 6.2 101.9% View Chart
Dividend Yield % 3.2 0.1 3,726.1%  

Financials

 TORRENT PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
FULFORD INDIA
Mar-14
TORRENT PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,720942 182.6%   
Low Rs1,134450 251.9%   
Sales per share (Unadj.) Rs394.5691.4 57.1%  
Earnings per share (Unadj.) Rs101.811.5 888.0%  
Cash flow per share (Unadj.) Rs116.315.4 757.4%  
Dividends per share (Unadj.) Rs40.002.00 2,000.0%  
Dividend yield (eoy) %2.80.3 975.6%  
Book value per share (Unadj.) Rs200.3380.0 52.7%  
Shares outstanding (eoy) m169.223.90 4,339.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.61.0 359.2%   
Avg P/E ratio x14.060.7 23.1%  
P/CF ratio (eoy) x12.345.3 27.1%  
Price / Book Value ratio x7.11.8 389.0%  
Dividend payout %39.317.4 225.2%   
Avg Mkt Cap Rs m241,4352,714 8,894.6%   
No. of employees `00010.90.4 2,453.2%   
Total wages/salary Rs m8,559505 1,694.8%   
Avg. sales/employee Rs Th6,129.66,073.0 100.9%   
Avg. wages/employee Rs Th785.81,137.4 69.1%   
Avg. net profit/employee Rs Th1,581.3100.7 1,570.7%   
INCOME DATA
Net Sales Rs m66,7642,696 2,476.0%  
Other income Rs m2,156125 1,719.6%   
Total revenues Rs m68,9202,822 2,442.4%   
Gross profit Rs m27,204-46 -58,628.7%  
Depreciation Rs m2,46115 16,188.2%   
Interest Rs m1,85910 19,565.3%   
Profit before tax Rs m25,04154 46,115.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,41410 66,810.4%   
Profit after tax Rs m17,22445 38,532.0%  
Gross profit margin %40.7-1.7 -2,367.8%  
Effective tax rate %25.617.7 144.9%   
Net profit margin %25.81.7 1,556.2%  
BALANCE SHEET DATA
Current assets Rs m46,6221,738 2,682.1%   
Current liabilities Rs m32,843545 6,029.6%   
Net working cap to sales %20.644.3 46.6%  
Current ratio x1.43.2 44.5%  
Inventory Days Days7448 153.2%  
Debtors Days Days794 1,835.3%  
Net fixed assets Rs m39,02912 327,973.9%   
Share capital Rs m84639 2,169.7%   
"Free" reserves Rs m31,4001,443 2,176.0%   
Net worth Rs m33,8901,482 2,286.8%   
Long term debt Rs m18,6370-   
Total assets Rs m90,1362,077 4,340.3%  
Interest coverage x14.56.7 215.5%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.71.3 57.0%   
Return on assets %21.22.6 811.2%  
Return on equity %50.83.0 1,685.0%  
Return on capital %48.54.3 1,127.5%  
Exports to sales %43.30-   
Imports to sales %6.924.5 28.1%   
Exports (fob) Rs m28,934NA-   
Imports (cif) Rs m4,584659 695.3%   
Fx inflow Rs m29,18517 169,682.6%   
Fx outflow Rs m6,021673 894.4%   
Net fx Rs m23,165-656 -3,531.4%   
CASH FLOW
From Operations Rs m27,13290 30,147.0%  
From Investments Rs m-7,014105 -6,705.8%  
From Financial Activity Rs m-14,352-14 101,783.7%  
Net Cashflow Rs m5,767181 3,194.7%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 3.8 184.7%  
FIIs % 12.6 0.1 12,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 21.2 41.5%  
Shareholders   26,511 4,783 554.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS